GLP-1 and Fatty Liver Disease (MASH): The First FDA-Approved Treatment

One in Three American Adults Has a Liver Problem They Don't Know About

About one in three adults in the United States has some degree of fat buildup in their liver. Most of them have no idea. The condition, now called metabolic dysfunction-associated steatotic liver disease (MASLD), produces no obvious symptoms in its early stages. No pain. No yellowing skin. Just a liver quietly accumulating fat while routine blood work comes back normal.

A 2025 modeling study published in JAMA Network Open by Dr. Phuc Le and colleagues at the Cleveland Clinic projected that MASLD prevalence among US adults will climb from 33.7% in 2020 to 41.4% by 2050 -- roughly 122 million people. The same model predicted that MASH cases will grow from 14.9 million to 23.2 million over the same period.

MASH (metabolic dysfunction-associated steatohepatitis) is where things get dangerous. Think of MASLD as the broader category -- fat in the liver. MASH is what happens when that fat triggers inflammation and the liver starts scarring. It is to MASLD what a house fire is to a cluttered garage: same starting point, very different outcomes. MASH can progress to cirrhosis, liver cancer, organ failure, and the need for a transplant. According to the FDA, about 6% of US adults -- 14.9 million people -- currently have MASH.

The trajectory keeps going. MASLD-related deaths are forecast to rise from 30,500 in 2020 to 95,300 by 2050. Liver transplants related to the disease could nearly quadruple, from about 1,717 per year to 6,720. MASH is on track to become the leading reason Americans need a new liver.

The overlap with everyday conditions is what makes this so easy to miss. According to NIH data, 80% to 90% of obese adults have some degree of MASLD. Between 50% and 70% of people with type 2 diabetes carry it too. Yet most are never told about their liver. The disease hides behind the conditions that cause it.

For the person reading this who has diabetes, carries extra weight, or has been told their cholesterol is off -- your liver deserves a conversation with your doctor. Not in five years. Now. Because a treatment that didn't exist two years ago just changed the math on what's possible.

From Diabetes Drug to Liver Treatment: Semaglutide's Unexpected Path

Semaglutide was not designed to treat liver disease. Novo Nordisk developed it as a GLP-1 receptor agonist -- a drug that mimics a gut hormone called glucagon-like peptide-1, which signals the brain to reduce appetite and tells the pancreas to release more insulin after meals. The FDA first approved it in 2017, and by the early 2020s, Wegovy (the brand name for the weight-loss dose) had become one of the most widely prescribed medications in the country for obesity and type 2 diabetes.

But liver researchers had a reason to pay attention. The biology connecting obesity, insulin resistance, and liver fat is not a loose association -- it is a causal chain. The pathophysiology of MASLD follows what scientists call a "two-hit" model, proposed by Day and James in 1998. The first hit is insulin resistance. When cells stop responding properly to insulin, the liver gets flooded with free fatty acids and triglycerides, building up fat deposits. The second hit is more destructive: that excess fat makes the liver vulnerable to oxidative stress, inflammation from adipose tissue (which pumps out TNF-alpha and interleukin-6), and a cascade of injury that causes hepatocyte ballooning, cell death, and eventually fibrosis.

A drug that attacks insulin resistance and produces substantial weight loss should, in theory, hit both stages. And researchers had evidence this worked. A landmark 2015 study by Dr. Eduardo Vilar-Gomez and colleagues showed that patients who achieved more than 10% weight loss saw 90% resolution of MASH and 45% regression of fibrosis. The problem? Sustaining that kind of weight loss through diet and exercise alone proved unrealistic for most patients. People tend to regain weight over time, and the liver damage returns with it.

Semaglutide offered something lifestyle interventions could not: consistency. Patients on the drug lose weight and keep it off because the drug continues working week after week. In the earlier phase 2 trial, published by Dr. Philip Newsome and colleagues in the New England Journal of Medicine in 2021, semaglutide demonstrated resolution of MASH activity -- but did not show statistically significant improvement in fibrosis. The liver inflammation got better; the scarring did not. That was good, but not enough for FDA approval as a MASH treatment.

Then came the ESSENCE trial, and the fibrosis numbers changed. On August 15, 2025, the FDA approved Wegovy for adults with MASH and moderate-to-advanced fibrosis. It was the first GLP-1 therapy approved specifically for liver disease, and it came through the accelerated approval pathway with breakthrough therapy designation -- reserved for drugs that address serious conditions with substantial unmet need.

As Dr. Grace L. Su, president of AASLD, put it: "This approval represents an exciting turning point in how we approach liver disease treatment. It integrates liver health into overall wellness."

62.9% Resolution: Breaking Down the ESSENCE Trial Numbers

The ESSENCE trial (NCT04822181) is the clinical evidence behind the FDA's decision. Understanding what those numbers mean -- and what they don't mean -- matters if you're trying to figure out whether this treatment could apply to you or someone you know.

The trial design was substantial: 1,197 adults with biopsy-confirmed MASH and stage 2 or 3 liver fibrosis enrolled across 253 clinical sites in 37 countries. Participants were randomly assigned in a 2:1 ratio -- two-thirds got semaglutide 2.4 mg injected weekly, one-third got placebo. Everyone also received standard lifestyle counseling: dietary modification, physical activity, and stable doses of whatever medications they were already taking for cholesterol, blood sugar, or weight management.

The planned interim analysis looked at 800 participants at week 72. Here is what they found:

Endpoint	Semaglutide	Placebo	Difference
MASH resolution without worsening fibrosis	62.9%	34.3%	+28.6 points
Fibrosis improvement without worsening MASH	36.8%	22.4%	+14.4 points
Both outcomes combined	32.7%	16.1%	+16.6 points
Mean body weight change	-10.5%	-2.0%	-8.5 points

All primary endpoints hit statistical significance at P<0.001. The 62.9% MASH resolution rate is particularly notable because this was measured by liver biopsy, not blood tests or imaging. Pathologists looked at actual tissue samples and assessed whether the hallmarks of MASH -- the hepatocyte ballooning, the lobular inflammation -- had resolved.

The fibrosis result is the one that clinicians watched most closely. As Dr. Paul Kwo, Director of Hepatology at Stanford, noted in his expert review for the American College of Gastroenterology, the earlier phase 2 trial with semaglutide showed MASH resolution but failed to demonstrate fibrosis improvement. ESSENCE changed that. For the first time, a GLP-1 drug showed it could improve liver scarring -- not just inflammation.

The weight loss numbers help explain part of the mechanism. Patients on semaglutide lost an average of 10.5% of their body weight, right in the range that the Vilar-Gomez study identified as the threshold for substantial liver improvement. But the FDA noted that semaglutide may work through "potentially other mechanisms not fully understood," suggesting the drug's effect on the liver goes beyond weight loss alone.

What the trial does NOT tell us yet: The ESSENCE trial is still running. Part 2 continues to week 240 (about 4.6 years total) and will measure whether these histological improvements translate into fewer people developing cirrhosis, needing liver transplants, or dying from liver-related causes. The FDA approval was granted based on the biopsy data as a surrogate endpoint -- meaningful, but not the final word.

There are also equity gaps in the data. Both the HBSN editorial analysis and Dr. Kwo's review flagged low representation of Black patients in the trial, as well as limited data on people with "lean MASH" -- those who develop the disease without obesity. These populations may respond differently to treatment, and the current data cannot confirm that they will see the same benefits.

On safety: 86.3% of semaglutide patients reported at least one adverse event, compared with 79.7% on placebo. The gap is narrower than you might expect, and most of the excess was gastrointestinal -- nausea, diarrhea, vomiting, constipation. Only 2.6% of semaglutide patients discontinued treatment due to side effects, compared with 3.3% of placebo patients. The drug was tolerable for the vast majority of participants.

Could Your Metabolism Be Silently Damaging Your Liver?

MASLD earns its full name because the metabolic dysfunction comes first. The liver fat is downstream. If you have the metabolic risk factors, the probability that your liver is already affected is uncomfortably high.

Current clinical guidelines recommend screening for people who meet this profile: type 2 diabetes or prediabetes, abdominal obesity (even if overall BMI looks normal), plus at least one additional metabolic risk factor -- high triglycerides, low HDL cholesterol, or high blood pressure. Persistent elevation of liver enzymes (ALT, AST) on routine blood work is another trigger, though many MASLD patients have completely normal liver enzymes.

The screening process does not require a biopsy upfront. The recommended first step is the FIB-4 index, a simple calculation that uses four numbers your doctor already has: your age, AST level, ALT level, and platelet count. A FIB-4 score below 1.3 indicates low risk for advanced fibrosis -- recheck in one to three years. A score between 1.3 and 2.67 falls into an indeterminate zone that warrants either imaging (usually elastography, which measures liver stiffness) or a period of aggressive lifestyle intervention followed by retesting. Scores above 2.67 suggest possible advanced fibrosis and should prompt referral to a hepatologist.

FIB-4 Score	Risk Level	Next Step
Below 1.3	Low risk	Recheck in 1-3 years
1.3 - 2.67	Indeterminate	Elastography or lifestyle intervention + retest
Above 2.67	Possible advanced fibrosis	Hepatology referral

One misconception worth addressing: you do not have to be obese to develop MASLD. As Dr. Leana Wen noted in CNN, smaller "metabolically unhealthy" individuals also develop the disease. The clinical criteria for metabolic dysfunction include a BMI as low as 25 (or 23 for people of Asian ancestry), a waist circumference above 94 cm for men or 80 cm for women of European ancestry, or fasting blood sugar in the prediabetic range (100-125 mg/dL).

There are also ethnic disparities in prevalence. MASLD is most common among Hispanic Americans, followed by non-Hispanic White and Asian American populations, and less common in non-Hispanic Black individuals. These patterns do not mean any group is safe -- they mean screening conversations need to be tailored, not avoided.

If you have type 2 diabetes and have never had your liver assessed beyond a basic metabolic panel, you are among the majority. Most people with diabetes-related fatty liver have never been told about it. That is a screening failure, not a sign that your liver is fine. Ask your doctor about FIB-4 at your next visit. The calculation takes about thirty seconds. For more on supporting liver health alongside medical treatment, see our guide to liver support supplements including milk thistle and NAC.

Two FDA-Approved Drugs, Two Different Mechanisms

Semaglutide is not the first drug approved for MASH. That distinction belongs to resmetirom (brand name Rezdiffra), which the FDA approved in March 2024 based on the MAESTRO-NASH phase 3 trial. The two drugs work through completely different biological pathways, which is why comparing them matters -- and why combination therapy may eventually become the standard.

Feature	Semaglutide (Wegovy)	Resmetirom (Rezdiffra)
Mechanism	GLP-1 receptor agonist (weight loss, insulin sensitivity, inflammation)	Thyroid hormone receptor-beta agonist (hepatic lipid metabolism)
Administration	Weekly subcutaneous injection	Daily oral pill
MASH resolution rate	62.9%	25.9-29.9%
Fibrosis improvement	36.8%	24.2-25.9%
Weight loss	-10.5%	Minimal
FDA approval	August 2025	March 2024
Approval type	Accelerated	Accelerated
Indicated population	MASH with F2/F3 fibrosis	MASH with F2/F3 fibrosis

The MASH resolution numbers favor semaglutide considerably -- 62.9% versus roughly 26-30% for resmetirom. But these come from different trials with different patient populations, and no head-to-head study exists. Direct comparison requires caution.

Where semaglutide has a clear structural advantage is its effect beyond the liver. The drug already carries FDA approvals for obesity, type 2 diabetes, and cardiovascular risk reduction. For a patient with MASH who also has diabetes and heart disease risk -- which describes the majority of MASH patients -- semaglutide addresses multiple problems with a single weekly injection. As Dr. Kwo observed, "the vast majority of my patients with MASH have features of metabolic syndrome, including type 2 diabetes."

Resmetirom targets the liver more directly by activating thyroid hormone receptor-beta, which accelerates hepatic fat metabolism. It does not produce significant weight loss. For patients who cannot tolerate GLP-1 side effects or who do not need weight management, resmetirom offers a different entry point.

Both approvals are conditional. The HBSN editorial emphasized that both drugs were approved based on histological endpoints (tissue biopsy results), not clinical outcomes like survival or transplant-free years. Ongoing trials will determine whether the improvements visible under a microscope translate into fewer people dying from liver disease.

The pipeline is not limited to these two. A phase 2 trial of tirzepatide (a dual GIP/GLP-1 receptor agonist) showed MASH resolution rates of up to 62% at the highest dose, putting it in semaglutide's range. Survodutide, a dual glucagon/GLP-1 agonist, achieved 63-67% liver fat reduction in its phase 2 trial. Both are advancing into larger studies.

There are also real concerns about access. Wegovy's list price runs approximately $1,349 per month without insurance. Novo Nordisk has made the drug available for $499 per month through its NovoCare direct pharmacy, and savings programs can bring the cost down further for some patients. But for the millions of Americans with MASH, cost remains a barrier -- particularly when insurance coverage for the MASH indication is still being worked out across payers. For a broader overview of GLP-1 medications and what to know before starting one, see our GLP-1 weight loss drugs safety guide.

One important limitation for semaglutide specifically: it has not demonstrated efficacy in patients with cirrhosis. A small phase 2 trial of 71 patients with MASH-related cirrhosis by Dr. Rohit Loomba found significant weight loss but no statistically meaningful improvement in fibrosis or MASH resolution. GLP-1 drugs may also raise concerns about sarcopenia (muscle loss) in cirrhosis patients, a population where preserving muscle mass is already a clinical challenge.

The Metabolic Syndrome Connection: Why Your Liver Matters More Than You Think

Something gets lost when the conversation focuses only on the liver: MASLD is the hepatic manifestation of metabolic syndrome. The liver is not a separate problem. It is the organ that shows the damage earliest and most visibly when the whole metabolic system is under strain.

Metabolic syndrome -- the cluster of conditions including central obesity, high blood sugar, high triglycerides, low HDL, and high blood pressure -- affects a large fraction of American adults. And the liver sits at the center of it. Insulin resistance drives fat into the liver. Inflammation from excess adipose tissue damages hepatocytes. The liver, in turn, amplifies the metabolic dysfunction by producing more glucose and inflammatory signals. It is a feedback loop, and breaking it at any point helps the entire system.

This is where semaglutide's profile becomes particularly relevant. Beyond the MASH data, the drug has demonstrated cardiovascular benefits in people with obesity (the SELECT trial), kidney protection in people with type 2 diabetes (the FLOW trial), and reductions in major adverse cardiovascular events. Dr. Kwo's review cited retrospective data from Dr. Fasiha Kanwal and colleagues, published in JAMA Internal Medicine in 2024, suggesting that GLP-1 receptor agonists can reduce rates of hepatic decompensation -- the point where the liver begins failing.

For someone with metabolic syndrome, the calculus is straightforward but worth spelling out. Cardiovascular disease is the leading cause of death in people with MASLD and MASH who do not have advanced fibrosis. Not liver failure -- heart attacks and strokes. A treatment that improves the liver while also reducing cardiovascular risk addresses the actual leading killer in this population.

The practical question: If you already take a GLP-1 medication for diabetes or weight management, should you assume your liver is being treated? Not necessarily. The MASH indication is specifically for the 2.4 mg weekly dose. If you are on a lower dose or on a different GLP-1 (like liraglutide or dulaglutide), the ESSENCE trial data does not directly apply. Talk with your prescriber about whether dose adjustment or liver-specific monitoring makes sense.

The JAMA Network Open projection model carried an optimistic footnote: effective preventive and management strategies could minimize the forecasted burden. Two years ago, "effective management strategies" for MASH meant telling patients to lose weight and exercise -- advice that is correct but, for most people, unsustainable without pharmacological support. Now there are two FDA-approved drugs, a pipeline of next-generation treatments, and growing evidence that addressing metabolic syndrome treats the liver along with everything else.

The gap that remains is awareness. Most Americans with fatty liver do not know they have it. Most primary care visits for diabetes do not include a FIB-4 calculation. The treatment exists now; the screening infrastructure to match it does not. That is the bottleneck, and it is one that patients can push on by asking the right questions at their next appointment.

Frequently Asked Questions

Is semaglutide a cure for fatty liver disease?

No. Semaglutide treats MASH (the inflammatory, scarring stage of fatty liver disease) and can resolve the condition in a majority of patients, but it is not a cure for the broader spectrum of MASLD. The FDA approval is specifically for MASH with moderate-to-advanced fibrosis (stages F2-F3). Patients still need ongoing lifestyle changes, and the drug must be continued to maintain benefits. If you stop taking it, the metabolic drivers of the disease remain.

How do I know if I have MASH and should talk to my doctor?

Most people with MASH have no symptoms. If you have type 2 diabetes, prediabetes, obesity, or multiple metabolic risk factors (high blood pressure, high triglycerides, low HDL), ask your doctor about a FIB-4 score -- a simple calculation using routine blood work. If your score suggests possible fibrosis, your doctor can order additional testing like liver elastography. Do not wait for symptoms like yellowing skin or abdominal swelling; those indicate advanced disease.

Can I take semaglutide for MASH if I am not overweight?

The ESSENCE trial enrolled patients with MASH and stage 2-3 fibrosis regardless of BMI, but the trial had limited representation of lean MASH patients. The FDA approval does not restrict use by weight. However, because the data on lean patients is thin, your hepatologist will need to weigh the available evidence for your specific situation.

What is the difference between MASLD and MASH?

MASLD (metabolic dysfunction-associated steatotic liver disease) is the umbrella term for any fatty liver associated with metabolic risk factors. MASH (metabolic dysfunction-associated steatohepatitis) is the more severe subset where the fat has caused inflammation and liver cell damage, with or without fibrosis. Think of MASLD as the spectrum and MASH as the danger zone within it. Not everyone with MASLD progresses to MASH, but everyone with MASH started with MASLD.

How much does Wegovy cost for MASH treatment?

Wegovy's list price is approximately $1,349 per month without insurance. Novo Nordisk offers a $499/month price through its NovoCare direct pharmacy, and savings programs may reduce costs further. Insurance coverage for the MASH-specific indication is evolving -- check with your insurer and ask about prior authorization requirements. The FDA's new approval may expand coverage over time.